Participation in colorectal cancer screening: A review

Journal of the National Cancer Institute

Volumn 89, Issue 19, 1997, Pages 1406-1422

  Vernon, Sally W ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; COLORECTAL CANCER; DEMOGRAPHY; FEMALE; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OCCULT BLOOD; PRACTICE GUIDELINE; REVIEW; SIGMOIDOSCOPY;

EID: 0030921194     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.19.1406     Document Type: Review

References (214)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 1997;47:68]. CA Cancer J Clin 1997;47:5-27.
2. National Cancer Institute. Kosary CL, Ries LAG, Miller BA et al. editors. SEER Cancer Statistics Review, 1973-1992: Tables and Graphs. Bethesda (MD): National Cancer Institute, 1995.
3. American Cancer Society. Cancer facts & figures - 1996. Atlanta: American Cancer Society, Inc., 1996.
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
5. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
6. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study [published erratum appears in N Engl J Med 1993;329:672]. N Engl J Med 1993; 328:1365-71.
7. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-5.
8. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7.
9. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993;85:1311-8.
10. Atkin WS, Cuzick J, Northover JM, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet 1993;341:736-40.
11. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
12. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993;15:499-545.
13. National Cancer Institute. Working guidelines for early cancer detection: rationale and supporting evidence to decrease mortality. Bethesda (MD): National Cancer Institute, 1987.
14. U.S. Department of Health and Human Services. Healthy people 2000: national health promotion and disease prevention objectives. Washington (DC): U.S. Department of Health and Human Services, 1996.
15. National Cancer for Health Statistics (NCHS). Health, United States, 1992 and healthy people 2000 review. Hyattsville (MD): U.S. Department of Health and Human Services, 1993.
16. Anderson LM, May DS. Has the use of cervical, breast, and colorectal cancer screening increased in the United States? Am J Public Health 1995;85:840-2.
17. National Cancer Institute. Edwards BK, Kessler LG, Ries LAG, editors. Cancer statistics review, 1973-1986: including a report on the status of cancer control: May 1989. Bethesda (MD): National Cancer Institute, 1989.
18. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin 1997;47:154-60.
19. Solomon MJ, McLeod RS. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1994;150:1961-70.
20. U.S. Preventive Services Task Force. DiGuiseppi C, Atkins D, Woolf SH, editors. Guide to clinical preventive services. 2nd ed. Baltimore (MD): Williams & Wilkins, 1996.
21. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
22. Weed DL. Methodologic guidelines for review papers. J Natl Cancer Inst 1997;89:6-7.
23. Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer 1971;28:131-4.
24. Brown ML, Potosky AL, Thompson GB, Kessler LG. The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey. Prev Med 1990;19:562-74.
25. Centers for Disease Control and Prevention. Trends in cancer screening - United States, 1987 and 1992. MMWR 1995;45:57-61.
26. Bat L, Pines A, Ron E, Niv Y, Arditi E, Shemesh E. A community-based program of colorectal screening in an asymptomatic population: evaluation of screening tests and compliance. Am J Gastroenterol 1986;81: 647-51.
27. Bejes C, Marvel MK. Attempting the improbable: offering colorectal cancer screening to all appropriate patients. Fam Pract Res J 1992;12: 83-90.
28. Box V, Nichols S, Lallemand RC, Pearson P, Vakil PA. Haemoccult compliance rates and reasons for non-compliance. Public Health 1984;98: 16-25.
29. Burack RC, Liang J. The early detection of cancer in the primary-care setting: factors associated with the acceptance and completion of recommended procedures. Prev Med 1987;16:739-51.
30. Cuckle HS, Wald NK, Butler EB. Compliance with screening for colorectal cancer. Br Med J 1986;293:628.
31. Elliot MS, Levenstein JH, Wright JP. Faecal occult blood testing in the detection of colorectal cancer. Br J Surg 1984;71:785-6.
32. Farrands PA, Griffiths RL, Britton DC. The Frome experiment - value of screening for colorectal cancer. Lancet 1981;1:1231-2.
33. Farrands PA, Hardcastle JD, Chamberlain J, Moss S. Factors affecting compliance with screening for colorectal cancer. Community Med 1984; 6:12-9.
34. Frame PS, Kowulich BA. Stool occult blood screening for colorectal cancer. J Fam Pract 1982;15:1071-5.
35. Goodman MJ. Mass screening for colorectal cancer - a negative report. JAMA 1977;237:2380.
36. Halper MS, Winawer S, Brody RS, et al. Issues of patient compliance. Colorectal cancer: prevention, epidemiology, and screening. New York: Raven Press, 1980:299-310.
37. Hardcastle JD, Armitage NC, Chamberlain J, Amar SS, James PD, Balfour TW. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer 1986;58:397-403.
38. Hart AR, Gay SP, Donnelly A, Griffin L, Inglis A, Mayberry MK, et al. Screening for colorectal cancer in Market Harborough, UK: a community-based programme. Eur J Gastroenterol Hepatol 1994;6:519-22.
39. Hobbs FD, Cherry RC, Fielding JW, Pike L, Holder R. Acceptability of opportunistic screening for occult gastrointestinal blood loss. BMJ 1992; 304:483-6.
40. Hoogewerf PE, Hislop TG, Morrison BJ, Burns SD, Sizto R. Patient compliance with screening for fecal occult blood in family practice. Can Med Assoc J 1987;137:195-8.
41. Joseph A. Compliance with fecal occult blood testing: the role of restrictive diets. Am J Public Health 1988;78:839-41.
42. King J, Fairbrother G, Thompson C, Morris DL. Colorectal cancer screening: optimal compliance with postal faecal occult blood test. Aust N Z J Surg 1992;62:714-9.
43. Lallemand RC, Vakil PA, Pearson P, Box V. Screening for asymptomatic bowel cancer in general practice. Br Med J 1984;288:31-3.
44. Macrae FA, Hill DJ, St. John DJ, Ambikapathy A, Garner JF. Predicting colon cancer screening behavior from health beliefs. Prev Med 1984;13: 115-26.
45. Mant D, Fuller A, Northover J, Astrop P, Chivers A, Crockett A, et al. Patient compliance with colorectal cancer screening in general practice. Br J Gen Pract 1992;22:18-20.
46. Million R, Howarth J, Turnberg E, Turnberg LA. Faecal occult blood testing for colorectal cancer in general practice. Practitioner 1982;226: 659-63.
47. Myers RE, Trock BJ, Lerman C, Wolf T, Ross E, Engstrom PF. Adherence to colorectal cancer screening in an HMO population. Prev Med 1990;19:502-14.
48. Myers RE, Ross EA, Wolf TA, Balshem A, Jepson C, Millner L. Behavioral interventions to increase adherence in colorectal cancer screening. Med Care 1991;29:1039-50.
49. Myers RE, Ross E, Jepson C, Wolf T, Balshem A, Millner L, et al. Modeling adherence to colorectal cancer screening. Prev Med 1994;23: 142-51.
50. Nichols S, Koch E, Lallemand RC, Heald RJ, Izzard L, Machin D, et al. Randomised trial of compliance with screening for colorectal cancer. Br Med J 1986;293:107-10.
51. Park SI, Saxe JC, Weesner RE. Does use of the Coloscreen Self-Test improve patient compliance with fecal occult blood screening? Am J Gastroenterol 1993;88:1391-4.
52. Plaskon PP, Fadden MJ. Cancer screening utilization: is there a role for social work in cancer prevention? Soc Work Health Care 1995;21:59-70.
53. Pye G, Christie M, Chamberlain JO, Moss SM, Hardcastle JD. A comparison of methods for increasing compliance within a general practitioner based screening project for colorectal cancer and the effect on practitioner workload. J Epidemiol Community Health 1988;42:66-71.
54. Robinson MH, Pye G, Thomas WM, Hardcastle JD, Mangham CM. Haemoccult screening for colorectal cancer: the effect of dietary restriction on compliance. Eur J Surg Oncol 1994;20:545-8.
55. Sangster JF, Gerace TM, Bass MJ. Hemoccult II screening for bowel cancer: will family practice patients accept it? Can Fam Physician 1986; 32:289-95.
56. Sontag SJ, Durczak C, Aranha GV, Chejfec G, Frederick W, Greenlee HB. Fecal occult blood screening for colorectal cancer in a Veterans Administration Hospital. Am J Surg 1983;145:89-94.
57. Stewart HL, Wiens E. Hemoccult test as a routine screening procedure for colorectal disease in the private clinic setting. Can J Surg 1979;22:572-4.
58. Struewing JP, Pape DM, Snow DA. Improving colorectal cancer screening in a medical residents' primary care clinic. Am J Prev Med 1991;7: 75-81.
59. Thomas WM, Pye G, Hardcastle JD, Mangham CM. Faecal occult blood screening for colorectal neoplasia: a randomized trial of three days or six days of tests. Br J Surg 1990;77:277-9.
60. Thompson RS, Michnich ME, Gray J, Friedlander L, Gilson B. Maximizing compliance with hemoccult screening for colon cancer in clinical practice. Med Care 1986;24:904-14.
61. Verne J, Kettner J, Mant D, Farmer A, Mortenson N, Northover J. Self-administered faecal occult blood tests do not increase compliance with screening for colorectal cancer: results of a randomized controlled trial. Eur J Cancer Prev 1993;2:301-5.
62. Robinson MH, Marks CG, Farrands PA, Bostock K, Hardcastle JD. Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up. Br J Surg 1996;83:500-1.
63. Adamsen S, Kronborg O. Acceptability and compliance in screening for colorectal cancer with focal occult blood test. Scand J Gastroenterol 1984; 19:531-1.
64. Bralow SP, Kopel J. Hemoccult screening for colorectal cancer. An impact study on Sarasota, Florida. J Fla Med Assoc 1979;64:915-9.
65. Chambers KJ, Morgan BP. Colorectal cancer and hemoccult. Aust N Z J Surg 1980;50:464-7.
66. Chang FC, Jackson TM, Jackson CR. Hemoccult screening for colorectal cancer. Am J Surg 1988;156:457-9.
67. Cummings KM, Michalek A, Mettlin C, Mittelman A. Screening for colorectal cancer using the Hemoccult II stool guaiac slide test. Cancer 1984;53:2201-5.
68. Cummings KM, Michalek A, Tidings J, Herrera L, Mettlin C. Results of a public screening program for colorectal cancer. N Y State J Med 1986; 86:68-72.
69. Faivre J, Arveux P, Milan C, Durand G, Lamour J, Bedenne L. Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy Study. Eur J Cancer Prev 1991;1:49-55.
70. Hastings JB. Mass screening for colorectal cancer. Am J Surg 1974;127: 228-33.
71. Herbert C, Launoy G, Thezee Y, Maurel J, Richir B, Reaud JM, et al. Participants' characteristics in a French colorectal cancer mass screening campaign. Prev Med 1995;24:498-502.
72. Heeb MA, Ahlvin RC. Screening for colorectal carcinoma in a rural area. Surgery 1978;83:540-1.
73. Heim CR, Rhodes DF, Burger MC, Spickard WA. Evaluation of positive Hemoccult test results obtained in a community screening program. J Tenn Med Assoc 1986;79:755-8.
74. Jansen JH. Participation in the first and second round of a mass-screening for colorectal cancer. Soc Sci Med 1984;18:633-6.
75. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68 308 subjects. Scand J Gastroenterol 1994;29:468-73.
76. Khubchandani IT, Karamchandani MC, Kleckner FS, Sheets JA, Stasik JJ, Rosen L, et al. Mass screening for colorectal cancer. Dis Colon Rectum 1989;32:754-8.
77. Larkin KK. Mass screening in colorectal cancer. Aust N Z J Surg 1980; 50:467-9.
78. McGarrity TJ, Long PA, Peiffer LP, Converse JO, Kreig AF. Results of a television-advertised public screening program for colorectal cancer. Arch Intern Med 1989;149:140-4.
79. McGarrity TJ, Long PA, Peiffer LP. Results of a repeat television-advertised mass screening program for colorectal cancer using fecal occult blood tests. Am J Gastroenterol 1990;85:266-70.
80. Miller SF, Knight AR. The early detection of colorectal cancer. Cancer 1977;40:945-9.
81. Miller MP, Stanley TV. Results of a mass screening program for colorectal cancer. Arch Surg 1988;123:63-5.
82. Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA. A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg 1991;161:101-6.
83. Morrow GR, Way J, Hoagland AC, Cooper R. Patient compliance with self-directed Hemocult testing. Prev Med 1982;11:512-20.
84. Niv Y. Does a risk questionnaire add anything to a colorectal screening project? Report of a 3-year screening experience. J Clin Gastroenterol 1992;15:33-6.
85. Petrelli NJ, Palmer M, Michalek A, Herrera L, Mink I, Bersani G, et al. Massive screening for colorectal cancer. A single institute's public commitment. Arch Surg 1990;125:1049-51.
86. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol 1994;3:27-36.
87. Slater PE, Fich A, Zimmerman J, Ever-Hadani P, Rachmilewitz D. Recruitment of subjects for fecal occult blood screening: a comparison of two methods in Jerusalem. J Clin Gastroenterol 1985;7:51-4.
88. Sterchi JM. Screening for colorectal cancer. South Med J 1979;72: 1144-6.
89. Winchester DP, Shull JH, Scanlon EF, Murrell JV, Smeltzer C, Vrba P, et al. A mass screening program for colorectal cancer using chemical testing for occult blood in the stool. Cancer 1980;45:2955-8.
90. Winchester DP, Sylvester J, Maher ML. Risks and benefits of mass screening for colorectal neoplasia with the stool guaiac test. CA Cancer J Clin 1983;33:333-43.
91. Bostick RM, Sprafka JM, Virnig BA, Potter JD. Knowledge, attitudes, and personal practices regarding prevention and early detection of cancer. Prev Med 1993;22:65-85.
92. Byles JE, Sanson-Fisher RW, Redman S, Reid AL, Agrez M. Early detection of colorectal cancer: a profile of current practice. Cancer Detect Prev 1992;16:245-52.
93. Centers for Disease Control and Prevention. Screening for colorectal cancer - United States, 1992-1993, and new guidelines. JAMA 1996;275: 830-1.
94. Polednak AP. Knowledge of colorectal cancer and use of screening tests in persons 40-74 years of age. Prev Med 1990;19:213-26.
95. Price JH. Perceptions of colorectal cancer in a socioeconomically disadvantaged population. J Community Health 1993;18:347-62.
96. Weller DP, Owen N, Hiller JE, Willson K, Wilson D. Colorectal cancer and its prevention: prevalence of beliefs, attitudes, intentions and behaviour. Aust J Public Health 1995;19:19-23.
97. Dent OF, Bartrop R, Goulston KJ, Chapuis PH. Participation in faecal occult blood screening for colorectal cancer. Soc Sci Med 1983;17:1723: 17-23.
98. Fric P, Zavoral M, Dvorakova H, Zoubek V, Roth Z. An adapted program of colorectal cancer screening - 7 years experience and cost-benefit analysis. Hepatogastroenterology 1994;41:413-6.
99. Laville EA, Vernon SW, Jackson GL, Hughes JI. Comparison of participants and nonparticipants in a work site cancer awareness and screening program. J Occup Med 1989;31:221-32.
100. Lee FI. Screening for colorectal cancer in a factors-based population with Fecatest. Br J Cancer 1983;48:843-7.
101. Lee CY. A randomized controlled trial to motivate worksite fecal occult blood testing. Yonsei Med J 1991;32:131-8.
102. Silman A, Mitchell P. Attitudes of non-participants in an occupational based programme of screening for colorectal cancer. Community Med 1984;6:8-11.
103. Zoubek V, Zoubkova H. Results of screening for colorectal carcinoma in the District of Bruntal using the Haemoccult Test in 1985-1988. Czech Med 1990;13:52-7.
104. Elwood TW, Erickson A, Lieberman S. Comparative educational approaches to screening for colorectal cancer. Am J Public Health 1978;68: 135-8.
105. Weinrich SP, Weinrich MC, Stromborg MF, Boyd MD, Weiss HL. Using elderly educators to increase colorectal cancer screening. Gerontologist 1993;33:491-6.
106. Caffarey SM, Broughton CIM, Marks CG. Faecal occult blood screening for colorectal neoplasia in a targeted high-risk population. Br J Surg 1993;80:1399-400.
107. Cripps NPJ, Heald RJ. Family based colorectal cancer screening in a district hospital. Gut 1996;38:421-5.
108. Fruhmorgen P, Demling L. Early detection of colorectal carcinoma with a modified guaiactest: a screening examination in 6000 humans. Acta Gastroenterol Belg 1978;41:682-7.
109. Habba SF, Doyle JS. Colorectal cancer screening of asymptomatic patients in Ireland. Ir J Med Sci 1983;152:121-4.
110. Powe BD. Fatalism among elderly African Americans: effects on colorectal cancer screening. Cancer Nurs 1995;18:385-92.
111. Richardson JL, Danley K, Mondrus GT, Deapen D, Mack T. Adherence to screening examinations for colorectal cancer after diagnosis in a first-degree relative. Prev Med 1995;24:166-70.
112. Weinrich SP. Predictors of older adults' participation in fecal occult blood screening. Oncol Nurs Forum 1990;17:715-20.
113. Blalock SJ, DeVellis BM, Afifi RA, Sandler RS. Risk perceptions and participation in colorectal cancer screening. Health Psychol 1990;9: 792-806.
114. DeVellis BM, Blalock SJ, Sandler RS. Predicting participation in cancer screening: the role of perceived behavioral control. J Appl Soc Psychol 1990;20:639-60.
115. Sandler RS, DeVellis BM, Blalock SJ, Holland KL. Participation of high-risk subjects in colon cancer screening. Cancer 1989;63:2211-5.
116. Lipkus IM, Rimer BK, Lyna PR, Pradhan AA, Conaway M, Woods-Powell CT. Colorectal screening patterns and perceptions of risk among African-American users of a community health center. J Community Health 1996;21:409-27.
117. Hart AR, Jestico B, Antill C, Taylor M, Mayberry JF. Blood donor centres can effectively publicise cancer screening. Public Health 1996;110:247-9.
118. Gnauck R. Screening for colon cancer in Germany. Tumori 1995;81:30-7.
119. Thomas W, White CM, Mah J, Geisser MS, Church TR, Mandel JS. Longitudinal compliance with annual screening for fecal occult blood. Minnesota Colon Cancer Control Study. Am J Epidemiol 1995;142: 176-82.
120. Arveux P, Durand G, Milan C, Bedenne L, Levy D, Doan BD, et al. Views of a general population on mass screening for colorectal cancer: The Burgundy Study. Prev Med 1992;21:574-81.
121. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27700 subjects. Cancer 1988;62:645-51.
122. Klaaborg K, Madsen MS, Sondergaard O, Kronborg O. Participation in mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 1986;21:1180-4.
123. Kronborg O, Fenger C, Sondergaard O, Pedersen KM, Olsen J. Initial mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 1987;22:667-86.
124. Lindholm E, Berglund B, Haglind E, Kewenter J. Factors associated with participation in screening for colorectal cancer with faecal occult blood testing. Scand J Gastroenterol 1995;30:171-6.
125. Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107 349 subjects. Lancet 1989;1: 1160-4.
126. Kronborg O, Fenger C, Olsen J, Bech K, Sondergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989;24: 599-606.
127. Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L. Adherence to continuous screening for colorectal neoplasia. Med Care 1993;31:508-19.
128. Stephenson BM, Murday VA, Finan PJ, Quirke P, Dixon MF, Bishop DT. Feasibility of family based screening for colorectal neoplasia: experience in one general surgical practice. Gut 1993;34:96-100.
129. Schroy PC 3rd, Wilson S, Afdhal N. Feasibility of high-volume screening sigmoidoscopy using a flexible fiberoptic endoscope and a disposable sheath system. Am J Gastroenterol 1996;91:1331-7.
130. Krevsky B, Niewiarowski T, League R, Herman H, Matz L, Fisher RS. Flexible sigmoidoscopy screening in an industrial setting. Am J Gastroenterol 1992;87:1759-62.
131. Neale AV, Demers RY, Herman S. Compliance with colorectal cancer screening in a high-risk occupational group. J Occup Med 1989;31: 1007-12.
132. Vernon SW, Acquavella JF, Douglass TS, Hughes JI. Factors associated with participation in an occupational program for colorectal cancer screening. J Occup Med 1989;31:458-63.
133. Olynyk JK, Aquilia S, Fletcher DR, Dickinson JA. Flexible sigmoidoscopy screening for colorectal cancer in average-risk subjects: a community-based pilot project. Med J Aust 1996;165:74-6.
134. Kelly RB, Shank JC. Adherence to screening flexible sigmoidoscopy in asymptomatic patients. Med Care 1992;30;1029-42.
135. Selby JV, Friedman GD, Collen MF. Sigmoidoscopy and mortality from colorectal cancer: the Kaiser Permanente Multiphasic Evaluation Study. J Clin Epidemiol 1988;41:427-34.
136. Lewis SF, Jensen NM. Screening sigmoidoscopy. Factors associated with utilization. J Gen Intern Med 1996;11:542-4.
137. Lewis RJ, Lerman SE, Schnatter AR, Hughes JI, Vernon SW. Colorectal polyp incidence among polypropylene manufacturing workers. J Occup Med 1994;36:174-81.
138. Tilley BC, Johnson CC, Schultz LR, Buffler PA, Joseph CL. Risk of colorectal cancer among automotive pattern and model makers. J Occup Med 1990;32:541-6.
139. Hardcastle JD, Farrands PA, Balfour TW, Chamberlain J, Amar SS, Sheldon MG. Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet 1983;2:1-1.
140. Madlon-Kay DJ. Methods to encourage screening sigmoidoscopy examination. J Clin Gastroenterol 1986;8:701-2.
141. Rex DK, Lehman GA, Ulbright TM, Smith JJ, Pound DC, Hawes RH, et al. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. Am J Gastroenterol 1993;88:825-31.
142. Neilson AR, Whynes DK. Determinants of persistent compliance with screening for colorectal cancer. Soc Sci Med 1995;41:365-74.
143. Hoogewerf PE, Hislop TG, Morrison BJ, Burns SD, Sizto R. Health belief and compliance with screening for fecal occult blood. Soc Sci Med 1990; 30:721-6.
144. Hunter W, Farmer A, Mant D, Verne J, Northovor J, Fitzpatrick R. The effect of self-administered faecal occult blood tests on compliance with screening for colorectal cancer: results of a survey of those invited. Fam Pract 1991;8:367-72.
145. Hynam KA, Hart AR, Gay SP, Inglis A, Wicks AC, Mayberry JF. Screening for colorectal cancer: reasons for refusal of faecal occult blood testing in a general practice setting in England. J Epidemiol Community Health 1995;49:84-6.
146. Launoy G, Veret JL, Richir B, Reaud JM, Ollivier V, Valla A, et al. Involvement of general practitioners in mass screening. Experience of a colorectal cancer mass screening programme in the Calvados region (France). Eur J Cancer Prev 1993;2:229-32.
147. Vernon SW, Acquavella JF, Yarborough CM, Hughes JI, Thar WE. Reasons for participation and nonparticipation in a colorectal cancer screening program for a cohort of high risk polypropylene workers. J Occup Med 1990;32:46-51.
148. Vernon SW, Gilstrap EL, Jackson GL, Hughes JI. An intervention to increase participation in a work site cancer screening program. Health Values 1992;16:3-9.
149. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990;113: 373-84.
150. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995;109:1781-90.
151. Walker A, Whynes DK. Participation and screening programmes for colorectal cancer: More would be better? J Health Econ 1991;10:207-25.
152. Hart AR, Wicks AC, Mayberry JF. Colorectal cancer screening in asymptomatic populations. Gut 1995;36:590-8.
153. Wagner JL, Tunis S, Brown M, Chaing A, Almeida R. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Levin B, editors. Prevention and early detection of colorectal cancer. London: Saunders, 1996.
154. McCarthy BD, Moskowitz MA. Screening flexible sigmoidoscopy: patient attitudes and compliance. J Gen Intern Med 1993;8:120-5.
155. Williams CB, Macrae FA, Bartram CI. A prospective study of diagnostic methods in adenoma follow-up. Endoscopy 1982;14:74-8.
156. Durdey P, Weston PM, Williams NS. Colonoscopy or barium enema as initial investigation of colonic disease. Lancet 1987;2:549-51.
157. Maule WF. Screening for colorectal cancer by nurse endoscopists. N Engl J Med 1994;330:183-7.
158. Steine S. Which hurts the most? A comparison of pain rating during double-contrast barium enema examination and colonoscopy. Radiology 1994;191:99-101.
159. Elwood JM, Ali G, Schlup MM, McNoe B, Barbezat GO, North F, et al. Flexible sigmoidoscopy or colonoscopy for colorectal screening: a randomized trial of performance and acceptability. Cancer Detect Prev 1995; 19:337-47.
160. Feinleib M. New directions for community intervention studies [editorial]. Am J Public Health 1996;86:1696-8.
161. Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket Heart Health Program: community changes in cardiovascular risk factors and projected disease risk. Am J Public Health 1995;85: 777-85.
162. Winkleby MA, Taylor CB, Jatulis D, Fortmann SP. The long-term effects of a cardiovascular disease prevention trial: the Stanford Five-City Project. Am J Public Health 1996;86:1773-9.
163. Winkleby MA. The future of community-based cardiovascular disease intervention studies [editorial]. Am J Public Health 1994;84:1369-72.
164. Susser M. The tribulations of trials - intervention in communities [editorial]. Am J Public Health 1995;85:156-8.
165. Fisher EB Jr. The results of the COMMIT Trial. Community Intervention Trial for Smoking Cessation [editorial]. Am J Public Health 1995;85: 159-60.
166. Burack RC, Gimotty PA, George J, Simon MS, Dews P, Moncrease A. The effect of patient and physician reminders on use of screening mammonraphy in a health maintenance organization. Results of a randomized controlled trial. Cancer 1996;78:1708-21.
167. Champion V, Huster G. Effect of interventions on stage of mammographs adoption. J Behav Med 1995;18:169-87.
168. Reynolds KD, West SG, Aiken LS. Increasing the use of mammography: a pilot program. Health Educ Q 1990;17:429-41.
169. King ES, Rimer BK, Seay J, Balshem A, Engstrom PF. Promoting manmography use through progressive interventions: is it effective? Am J Public Health 1994;84:104-6.
170. Taplin SH, Anderman C, Grothaus L, Currs S, Montano D. Using physician correspondence and postcard reminders 10 promote mammography use. Am J Public Health 1944;84:571-4.
171. Skinner CS, Strecher VJ, Hospers H. Physicians' recommendations for mammography: do tailored messages make a difference? Am J Public Health 1994;84:43-9.
172. Urban N, Taplin SH, Taylor VM, Peacock S, Anderson G, Conrad D, et al. Community organization to promote breast cancer screening among women ages 50-75. Prev Med 1445;24:477-84.
173. Curry SJ, Taplin SH, Anderman C, Barlow WE, McBride C. A randomized trial of the impact of risk assessment and feedback on participation in mammography screening. Prev Med 1993;22:350-60.
174. Community intervention trial for smoking cessation (COMMIT): II. Changes in adult cigarette smoking prevalence. Am J Public Health 1995; 85:193-200.
175. Luepker RV, Murray DM, Jacobs DR Jr, Mittelmark MB, Bracht N, Carlaw R, et al. Community education for cardiovascular disease prevention: risk factor changes in the Minnesota Heart Health Program. Am J Public Health 1994;84:1383-93.
176. Fortmann SP, Taylor CB, Flora JA, Jatulis DC. Changes in adult cigarette smoking prevalence after 5 years of community health education: the Stanford Five-City Project. Am J Epidemiol 1993;137:82-46.
177. Centers for Disease Control and Prevention. State- and sex-specific prevalence of selected characteristics - behavioral risk fact surveillance system. 1992 and 1993. MMWR 1996;45:1-35.
178. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst 1994;86:997-1006.
179. Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst 1996;88:1706-7.
180. Marshall JR, Punch DP. Gender and illness behavior among colorectal cancer patients. Women Health 1986;11:67-82.
181. Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995;87:1747-54.
182. Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors. Am J Public Health 1996;86:1794-7.
183. Brenner H, Mielck A, Klein R, Ziegler H. The role of socioeconomic factors in the survival of patients with colorectal cancer in Saarland/ Germany. J Clin Epidemiol 1991;44:807-15.
184. Ball JK, Elixhauser A. Treatment differences between blacks and whites with colorectal cancer. Med Care 1996;34:970-84.
185. Mayberry RM, Coates RJ, Hill HA, Click LA, Chen VW, Austin DF, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst 1995;87:1686-93.
186. Dayal H, Polissar L, Yang CY, Dahlberg S. Race, socioeconomic status, and other prognostic factors for survival from colo-rectal cancer. J Chronic Dis 1987;40:857-64.
187. Gordon NP, Hiatt RA, Lampert DI. Concordance of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst 1993;85:566-70.
188. Kirkman-Liff B, Kronenfeld JJ. Access to cancer screening services for women. Am J Public Health 1992;82:733-5.
189. Mandelblatt J, Traxler M, Lakin P, Kanetsky P, Kao R. Targeting breast and cervical cancer screening to elderly poor black women: who will participate? Prev Med 1993;22:20-33.
190. Mamon JA, Shediac MC, Crosby CB, Sanders B, Matanoski GM, Celentano DD. Inner-city women at risk for cervical cancer: behavioral and utilization factors related to inadequate screening. Prev Med 1940;19: 363-76.
191. Screening mammography: The results of the NCI Breast Cancer Screening Consortium and National Health Interview Survey Studies. JAMA 1990;264:54-8.
192. Celentano DD, Shapiro S, Weismann CS. Cancer preventive screening behavior among elderly women. Prev Med 1982;11:454-63.
193. Kottke TE, Trapp MA, Fores MM, Kelly AW, Jung S, Novotny PJ, et al. Cancer screening behaviors and attitudes of women in southeastern Minnesota. JAMA 1995;273:1099-105.
194. Lerman C, Rimer B, Trock B, Balshem A, Engstrom PF. Factors associated with repeat adherence to breast cancer screening. Prev Med 1990; 19:274-90.
195. Rimer BK, Keintz MK, Kessler HB, Engstrom PF, Rosan JR. Why women resist screening mammography: patient-related barriers. Radiology 1989;172:243-6.
196. Zapka JG, Stoddard AM, Costanza MF, Greene HL. Breast cancer screening by mammography: utilization and associated factors. Am J Public Health 1989;79:1499-502.
197. Bernstein AB, Thompson GB, Harlan LC. Differences in rates of cancer screening by usual source of medical care. Med Care 1991;29:196-209.
198. Ettner SL. The timing of preventive services for women and children: the effect of having a usual source of care. Am J Public Health 1996;86: 1748-54.
199. Lieberman D. Screening/early detection model for colorectal cancer: Why screen? Cancer 1994;74:2023-7.
200. Ransohoff DF, Lang CA. Improving the fecal occult-blood test [editorial]. N Engl J Med 1996;334:189-90.
201. Lieberman D, Sleisenger MH. Is it time to recommend screening for colorectal cancer? Lancet 1996;348:1463-4.
202. Macrae FA. Screening for colorectal cancer, 1996. Med J Aust 1996;165: 102-5.
203. Annas GJ. Genetic prophecy and genetic privacy - can we prevent the dream from becoming a nightmare? [editorial]. Am J Public Health 1995; 85:1196-7.
204. Clayton EW, Steinberg KK, Khoury MJ, Thomson E, Andrews L, Kahn MJ, et al. Informed consent for genetic research on stored tissue samples. JAMA 1995;274:1786-92.
205. Garber JE, Schrag D. Testing for inherited cancer susceptibility [editorial]. JAMA 1996;275:1928-9.
206. Geller G, Bernhardt BA, Helzlsouer K, Holtzman NA, Stefanek M, Wilcox PM. Informed consent and BRCA1 testing [letter]. Nat Genet 1995; 11:364.
207. Holtzman NA. Are we ready to screen for inherited susceptibility to cancer? Oncology 1996;10:57-64.
208. Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med 1996;334:1192-4.
209. Hudson KL, Rothenberg KH, Andrews LB, Kahn MJ, Collins FS. Genetic discrimination and health insurance: an urgent need for reform. Science 1995;270:391-3.
210. Khoury MJ. From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. Am J Public Health 1996;86:1717-22.
211. Omenn GS. Comment: genetics and public health. Am J Public Health 1996;86:1701-4.
212. Stewart-Brown S, Farmer A. Screening could seriously damage your health [editorial]. BMJ 1997;314:533-4.
213. Solomon MJ. Screening for colorectal cancer: too early to be dogmatic [editorial]. Med J Aust 1996;165:68-9.
214. Krieger N, Zierler S. The need for epidermologic theory. Epidemiology 1997;8:212-4.